CDER personnel moves
This article was originally published in The Tan Sheet
GlaxoSmithKline NeuroHealth Specialty Division VP Shirley Murphy, MD, will become first director of FDA's Division of Pediatric Drug Development effective Sept. 9. Prior to joining GSK, Murphy was at the University of New Mexico, where she headed the Division of Pulmonary Medicine and chaired the Department of Pediatrics. She also is a previous chair of FDA's Pulmonary-Allergy Drugs Advisory Committee. Also, Victor Raczkowski, MD, will take over as Office of Drug Safety director Sept. 9. Raczkowski is currently ODE III deputy director and acting head of the Division of Gastrointestinal & Coagulation Drug Products. He participated in the June advisory committee review of AstraZeneca/P&G's OTC switch application for Prilosec 1...
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."